ReviewClinical, cosmetic and investigational dermatology2014
Psoriasis and comorbidities: links and risks.
Review in Clinical, cosmetic and investigational dermatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 2 syntheses or guidelines pooled it, 147 citations in OpenAlex.
- Prevalence and Possible Role ofMediators of inflammation · 2018Pooled it
- Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture.American journal of human genetics · 2015Pooled it
- Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial.The British journal of dermatology · 2021Trial
- Construction of risk prediction models for psoriasis based on 45 dietary nutrients using machine learning and SHAP analysis.Asia Pacific journal of clinical nutrition · 2026Article
- Image Processing for Diagnosing Psoriasis: A Machine Learning Approach to Classify Skin Lesions into Psoriasis Subtypes.Medical journal of the Islamic Republic of Iran · 2026Article
- Anti-IL-17 and Anti-IL-23 Therapies Modulate Serum Biomarkers of Intestinal Dysbiosis and Oxidative Stress Linked to Cardiovascular Risk in Patients with Psoriasis.Life (Basel, Switzerland) · 2025Article
- What drives patient cost variability in psoriasis care: a single centre study.BMC health services research · 2025Article
- Pharmacological Management of Psoriasis: Current Landscape and Future Perspectives.Recent advances in inflammation & allergy drug discovery · 2025Review
- Relationship between uncoupling protein 1 (UCP1) levels and psoriasis.Turkish journal of medical sciences · 2025Article
- A prospective Real-Life Multicenter Study of Tildrakizumab 200 mg in Patients with Moderate-Severe Psoriasis: Who is the Ideal Patient?Dermatology practical & conceptual · 2024Article
- Reverse causation between multiple sclerosis and psoriasis: a genetic correlation and Mendelian randomization study.Scientific reports · 2024Article
- Observational
- The association between psoriasis, psoriasis severity, and inflammatory bowel disease: a population-based analysis.Therapeutic advances in gastroenterology · 2024Article
- Lnc-HULC, miR-122, and sirtulin-1 as potential diagnostic biomarkers for psoriasis and their association with the development of metabolic syndrome during the disease course.Non-coding RNA research · 2023Article
- Proportions of Biologic Discontinuation Among Psoriasis Patients With Metabolic Comorbidities.Journal of psoriasis and psoriatic arthritis · 2023Article
- Gradually increasing the dosing interval of Secukinumab for moderate to severe plaque psoriasis: A single-center, uncontrolled, prospective study in 36 weeks.Dermatologic therapy · 2022Article
- Evaluation of the Role of Faecal Calprotectin in the Management of Psoriatic Patients under Treatment with Biologic Drugs.Biomedicines · 2022Article
- Impact of Psoriatic Disease on Quality of Life: Interim Results of a Global Survey.Dermatology and therapy · 2022Article
- Coptisine Alleviates Imiquimod-Induced Psoriasis-like Skin Lesions and Anxiety-like Behavior in Mice.Molecules (Basel, Switzerland) · 2022Article
- A Multivariate Analysis of Depression Prevalence in Psoriasis Patients: A Cohort Study.International journal of environmental research and public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic inflammatory skin disease affecting approximately 2% of the population worldwide. In the past decade, many studies have drawn attention to comorbid conditions in psoriasis. This literature review examines the epidemiological evidence, pathophysiological commonalities, and therapeutic implications for different comorbidities of psoriasis. Cardiovascular disease, obesity, diabetes, hypertension, dyslipidemia, metabolic syndrome, nonalcoholic fatty liver disease, cancer, anxiety and depression, and inflammatory bowel disease have been found at a higher prevalence in psoriasis patients compared to the general population. Because of the wide range of comorbid conditions associated with psoriasis, comprehensive screening and treatment must be implemented to most effectively manage psoriasis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.